Trials / Completed
CompletedNCT01366599
CV Events in Emetogenic Chemotherapy
Cardiovascular Events in Cancer Patients Receiving Highly Emetogenic or Moderately Emetogenic Chemotherapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 12,058 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Describe cardiovascular events in a cancer population receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC).
Detailed description
Patients were not recruited for nor enrolled in this study. This study is a retrospective observational study. Data from medical records or insurance claims databases are anonymised and used to develop a patient cohort. All diagnoses and treatment are recorded in the course of routine medical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HEC or MEC | Any HEC or MEC, including aprepitant |
Timeline
- Start date
- 2009-05-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2011-06-06
- Last updated
- 2017-05-24
Source: ClinicalTrials.gov record NCT01366599. Inclusion in this directory is not an endorsement.